TG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results and Business Update Investor Conference Call to be Held Today, Monday

TG Therapeutics, Inc. Announces

Third Quarter 2015 Financial Results and Business Update

Investor Conference Call to be

Held Today, Monday, November 9, 2015 at 8:30am ET

New York, NY, (November 9, 2015)

- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the third quarter ended September 30, 2015

and recent company developments.

Michael S. Weiss, the Company's

Executive Chairman and Interim Chief Executive Officer, stated, "During the third quarter, we achieved another major milestone

for the Company in obtaining a Special Protocol Assessment for our UNITY-CLL trial, a study evaluating the safety and efficacy

of our proprietary 1303' combination regimen in patients with front-line as well as previously treated CLL. This

is a very important and exciting clinical trial for the Company, as it represents our first pivotal trial for our proprietary

combination and, if successful, should provide a broad approval in CLL offering patients in both first-line and relapsed/refractory

setting, a novel, non-chemotherapy treatment option. Further, it would provide us a broad label for building additional three

and, possibly, four drug proprietary combinations to further improve outcomes for patients with CLL. With Phase 3 programs in

oncology now underway for both TG-1101 and TGR-1202, we're excited to begin exploring the potential of our pipeline products

for the treatment of autoimmune disease, an area where B-cell targeted therapies have proven highly effective, and anticipate

commencing our first trial in Multiple Sclerosis in the near-term." Mr. Weiss continued, "We also remain focused on

aggressively enrolling into our ongoing GENUINE Phase 3 clinical trial, and expect top-line data from this study in the second

half of 2016. Finally, from a financial perspective, with more than $115 million in cash and investments we have enough cash to

execute on our business plan."

Recent Developments and Highlights

Goals/Objectives for the Remainder

Financial Results for the

At September 30, 2015 the Company

had cash, cash equivalents, investment securities, and interest receivable of $115.4 million, which

includes approximately $67.0 million of net proceeds from the utilization

of the Company's at-the-market ("ATM") sales facility during the year (all of which was previously disclosed in connection

with our last quarterly update), as compared to December 31, 2014 when we had $78.9 million.

Our consolidated net loss for the

third quarter ended September 30, 2015, excluding non-cash items, was approximately $12.4 million, which included approximately

$6.9 million of manufacturing and CMC expenses in preparation for Phase 3 clinical trials and potential commercialization. The

consolidated net loss for the third quarter ended September 30, 2015, inclusive of non-cash items, was $13.7 million, or $0.28

per diluted share, compared to a consolidated net loss of $17.5 during the comparable quarter in 2014, representing a decrease

in consolidated net loss of $3.8 million. The decrease in consolidated net loss during the third quarter ended September 30, 2015

was primarily the result of $8.1 million of expense ($4.1 million of which was non-cash stock expense) recorded during the quarter

ended September 30, 2014 in conjunction with the Company's licensing agreement for TGR-1202, and a $2.9 million decrease

in non-cash compensation expense related to equity incentive grants over the comparable period in 2014. Partially offsetting the

aforementioned decreases, other research and development expenses for TG-1101 and TGR-1202 increased $4.8 million and $2.1 million,

respectively, over the comparable period in 2014.

Our consolidated net loss for the

nine months ended September 30, 2015, excluding non-cash items, was approximately $32.5 million, which included approximately

$16.0 million of manufacturing and CMC expenses in preparation for Phase 3 clinical trials and potential commercialization. The

consolidated net loss for the nine months ended September 30, 2015, inclusive of non-cash items, was $45.3 million, or $1.01 per

diluted share, compared to a consolidated net loss of $37.0 million during the comparable period in 2014, representing an increase

in consolidated net loss of $8.3 million. The increase in consolidated net loss during the nine months ended September 30, 2015

was primarily the result of other research and development expenses for TG-1101 and TGR-1202 increasing approximately $14.6 million

and $4.5 million, respectively, over the comparable period in 2014. This was offset by $9.3 million of expense ($5.3 million of

which was non-cash stock expense) recorded in conjunction with the Company's licensing agreements for TGR-1202 and the IRAK4

inhibitors program during the nine months ended September 30, 2014, and a decrease of $3.2 million in non-cash compensation expense

related to equity incentive grants over the comparable period in 2014.

Conference Call Information

The Company will host an investor

conference call today, November 9, 2015, at 8:30am ET, to discuss the Company's third quarter 2015 financial results and

provide a business outlook for the remainder of 2015.

In order to participate in the conference

call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Third Quarter 2015

Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media

section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available

for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical

company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune

diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a

novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes.

TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed

in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101

and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs

to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included

in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing

such trials and business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor program, and the anti-PD-L1 and anti-GITR antibodies

may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection

of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the

factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively

complete pre-clinical and clinical trials for TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR

antibodies; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101, TGR-1202,

the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies will not be reproduced in additional patients or in future

studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue,

the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the

completion of the current Phase 1 study; the risk that the combination of TG-1101 and TGR-1202, referred to as TG-1303, will not

prove to be a safe and efficacious backbone for triple and quad combination therapies; the risk that the data (both safety and

efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the

risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year;

our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports

filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as

of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or

circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com.

The information found on our website is not incorporated by reference into this press release and is included for reference purposes

Consolidated Financial Data

of Operations Information (Unaudited):

Condensed Balance Sheet Information:

* Condensed from audited financial